- Datum01.07.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Altan Cantürk
Moderator
Outlook Therapeutics Inc. Aktie
Verkaufen
Kaufen
Outlook Therapeutics Inc. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Outlook Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| L&S | VK | |||||
| Tradegate | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-4,19 %
Intraday
-9,60 %
1 Woche
-13,04 %
1 Monat
-15,34 %
Seit Jahresbeginn
-78,41 %
1 Jahr
-92,16 %
3 Jahre
-93,75 %
5 Jahre
Passender Service zu Outlook Therapeutics Inc.
Webinar zu Outlook Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,870-9,250
- Jahrestief / Hoch ($)1,060-2,595
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Outlook Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Outlook Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
